Your browser doesn't support javascript.
loading
Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.
Ma, Xiaoli; Rousseau, Vanessa; Sun, Haiji; Lantuejoul, Sylvie; Filipits, Martin; Pirker, Robert; Popper, Helmut; Mendiboure, Jean; Vataire, Anne-Lise; Le Chevalier, Thierry; Soria, Jean Charles; Brambilla, Elisabeth; Dunant, Ariane; Hainaut, Pierre.
Affiliation
  • Ma X; International Agency for Research on Cancer, Lyon, France.
  • Rousseau V; Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif, France.
  • Sun H; International Agency for Research on Cancer, Lyon, France.
  • Lantuejoul S; Department of Anatomy and Cytology, Centre Hospitalo-Universitaire, Albert Michallon, Grenoble, France.
  • Filipits M; Department of Medicine I, Medical University Vienna, Vienna, Austria.
  • Pirker R; Department of Medicine I, Medical University Vienna, Vienna, Austria.
  • Popper H; Institute of Pathology, Medical University of Graz, Austria.
  • Mendiboure J; Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif, France.
  • Vataire AL; Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif, France.
  • Le Chevalier T; Department of Medicine/Service des Innovations Thérapeutiques Précoces, Institut Gustave Roussy, Villejuif, France.
  • Soria JC; Department of Medicine/Service des Innovations Thérapeutiques Précoces, Institut Gustave Roussy, Villejuif, France; Institut National de la Santé et de la Recherche Médicale U981, Villejuif, France; Clinical and Translational Research Division, Institut Gustave Roussy, Villejuif, France.
  • Brambilla E; Department of Anatomy and Cytology, Centre Hospitalo-Universitaire, Albert Michallon, Grenoble, France.
  • Dunant A; Biostatistics and Epidemiology Unit, Institut Gustave Roussy, Villejuif, France.
  • Hainaut P; University of Strathclyde School of Global Public Health at iPRI, International Prevention Research Institute, Lyon, France; Institut Albert Bonniot, Institut National de la Santé et de la Recherche Médicale U 823, Grenoble, France. Electronic address: pierre.hainaut@i-pri.org.
Mol Oncol ; 8(3): 555-64, 2014 May.
Article in En | MEDLINE | ID: mdl-24495481
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Suppressor Protein p53 / Cisplatin / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Mutation / Antineoplastic Agents Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Middle aged Language: En Journal: Mol Oncol Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2014 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Suppressor Protein p53 / Cisplatin / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Mutation / Antineoplastic Agents Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Middle aged Language: En Journal: Mol Oncol Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2014 Document type: Article Affiliation country: